Developing a metagenomic view of xenobiotic metabolism

Pharmacological Research

Volumn 69, Issue 1, 2013, Pages 21-31

  Haiser, Henry J ^a   Turnbaugh, Peter J ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Hydrolysis; Metagenomics; Microbiome; Microbiota; Reduction; Xenobiotics

Indexed keywords

AZO COMPOUND; BALSALAZIDE; BETA GLUCURONIDASE INHIBITOR; CALCITONIN; CARBENOXOLONE; CHLORAMPHENICOL; CHOLINE; CLONAZEPAM; DIGOXIN; DRUG METABOLITE; ENZYME INHIBITOR; EQUOL; HERBICIDE; HESPERIDIN; INSULIN; IRINOTECAN; ISOFLAVONE DERIVATIVE; ISOSORBIDE DINITRATE; LACTULOSE; LEVODOPA; METHOTREXATE; MICROBIAL ENZYME; MISONIDAZOLE; OMEPRAZOLE; PRODRUG; SALAZOSULFAPYRIDINE; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT; ZONISAMIDE;

ACTINOBACTERIA; BACTERIAL GENE; BACTEROIDES; BIOREMEDIATION; BIOSYNTHESIS; BIOTRANSFORMATION; CARDIOVASCULAR DISEASE; CROHN DISEASE; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG METABOLISM; EGGERTHELLA LENTA; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FIRMICUTES; GENE EXPRESSION; GENE FUNCTION; GNOTOBIOTICS; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; METAGENOMICS; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MICROBIAL METABOLISM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEOBACTERIA; REVIEW; RHEUMATOID ARTHRITIS; SOIL MICROFLORA; SOYBEAN; ULCER; ULCERATIVE COLITIS; XENOBIOTIC METABOLISM;

ANIMALS; BIOTRANSFORMATION; GASTROINTESTINAL TRACT; HUMANS; METAGENOME; METAGENOMICS; XENOBIOTICS;

EID: 84873728735     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.07.009     Document Type: Review

References (133)

1. P.J. Turnbaugh, and A. Stintzi Human health and disease in a microbial world Frontiers in Microbiology 2 2011 190
2. T. Sousa, R. Paterson, V. Moore, A. Carlsson, B. Abrahamsson, and A.W. Basit The gastrointestinal microbiota as a site for the biotransformation of drugs International Journal of Pharmaceutics 363 2008 1 25
3. K.P. Lemon, G.C. Armitage, D.A. Relman, and M.A. Fischbach Microbiota-targeted therapies: an ecological perspective Science Translational Medicine 4 2012 137rv5
4. L. Dethlefsen, and D.A. Relman Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation Proceedings of the National Academy of Sciences of the United States of America 108 Suppl. 1 2011 4554 4561
5. L. Dethlefsen, S. Huse, M.L. Sogin, and D.A. Relman The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing PLoS Biology 6 2008 e280
6. P.J. Turnbaugh, F. Backhed, L. Fulton, and J.I. Gordon Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome Cell Host and Microbe 3 2008 213 223
7. P.J. Turnbaugh, V.K. Ridaura, J.J. Faith, F.E. Rey, R. Knight, and J.I. Gordon The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice Science Translational Medicine 1 2009 6ra14
8. A.W. Walker, J. Ince, S.H. Duncan, L.M. Webster, G. Holtrop, and X. Ze Dominant and diet-responsive groups of bacteria within the human colonic microbiota The ISME Journal 5 2011 220 230
9. N.P. McNulty, T. Yatsunenko, A. Hsiao, J.J. Faith, B.D. Muegge, and A.L. Goodman The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins Science Translational Medicine 3 2011 106ra
10. B.D. Wallace, H. Wang, K.T. Lane, J.E. Scott, J. Orans, and J.S. Koo Alleviating cancer drug toxicity by inhibiting a bacterial enzyme Science 330 2010 831 835
11. T.A. Clayton, D. Baker, J.C. Lindon, J.R. Everett, and J.K. Nicholson Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism Proceedings of the National Academy of Sciences of the United States of America 106 2009 14728 14733
12. Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, and B. DuGar Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 472 2011 57 63
13. J.J. Faith, F.E. Rey, D. O'Donnell, M. Karlsson, N.P. McNulty, and G. Kallstrom Creating and characterizing communities of human gut microbes in gnotobiotic mice The ISME Journal 4 2010 1094 1098
14. D.B. Gootenberg, and P.J. Turnbaugh Companion animals symposium: humanized animal models of the microbiome Journal of Animal Science 89 2011 1531 1537
15. J. Gans, M. Wolinsky, and J. Dunbar Computational improvements reveal great bacterial diversity and high metal toxicity in soil Science 309 2005 1387 1390
16. J. Davies How to discover new antibiotics: harvesting the parvome Current Opinion in Chemical Biology 15 2011 5 10
17. T.C. Galvão, W.W. Mohn, and V. de Lorenzo Exploring the microbial biodegradation and biotransformation gene pool Trends in Biotechnology 23 2005 497 506
18. V. Paliwal, S. Puranik, and H.J. Purohit Integrated perspective for effective bioremediation Applied Biochemistry and Biotechnology 166 2012 903 924
19. J. Gao, L.B. Ellis, and L.P. Wackett The University of Minnesota biocatalysis/biodegradation database: improving public access Nucleic Acids Research 38 2010 D488 D491
20. S. Fetzner, and F. Lingens Bacterial dehalogenases: biochemistry, genetics, and biotechnological applications Microbiological Reviews 58 1994 641 685
21. D.B. Janssen, I.J. Dinkla, G.J. Poelarends, and P. Terpstra Bacterial degradation of xenobiotic compounds: evolution and distribution of novel enzyme activities Environmental Microbiology 7 2005 1868 1882
22. M. Pavlova, M. Klvana, Z. Prokop, R. Chaloupkova, P. Banas, and M. Otyepka Redesigning dehalogenase access tunnels as a strategy for degrading an anthropogenic substrate Nature Chemical Biology 5 2009 727 733
23. M.P. McLeod, R.L. Warren, W.W. Hsiao, N. Araki, M. Myhre, and C. Fernandes The complete genome of Rhodococcus sp. Rha1 provides insights into a catabolic powerhouse Proceedings of the National Academy of Sciences of the United States of America 103 2006 15582 15587
24. R. van der Geize, and L. Dijkhuizen Harnessing the catabolic diversity of rhodococci for environmental and biotechnological applications Current Opinion in Microbiology 7 2004 255 261
25. D.R. Lovley, T. Ueki, T. Zhang, N.S. Malvankar, P.M. Shrestha, and K.A. Flanagan The microbe electric's physiology, ecology, and practical applications Advances in Microbial Physiology 59 2011 1 100
26. J. Yun, T. Ueki, M. Miletto, and D.R. Lovley Monitoring the metabolic status of Geobacter species in contaminated groundwater by quantifying key metabolic proteins with Geobacter-specific antibodies Applied and Environment Microbiology 77 2011 4597 4602
27. E.M. Top, and D. Springael The role of mobile genetic elements in bacterial adaptation to xenobiotic organic compounds Current Opinion in Biotechnology 14 2003 262 269
28. M.L. Cohen Epidemiology of drug resistance: implications for a post-antimicrobial era Science 257 1992 1050 1055
29. R.T. Mandelbaum, D.L. Allan, and L.P. Wackett Isolation and characterization of a Pseudomonas sp. that mineralizes the s-triazine herbicide atrazine Applied and Environment Microbiology 61 1995 1451 1457
30. M.L. de Souza, D. Newcombe, S. Alvey, D.E. Crowley, A. Hay, and M.J. Sadowsky Molecular basis of a bacterial consortium: interspecies catabolism of atrazine Applied and Environment Microbiology 64 1998 178 184
31. S. Radajewski, P. Ineson, N.R. Parekh, and J.C. Murrell Stable-isotope probing as a tool in microbial ecology Nature 403 2000 646 649
32. N. Reichardt, A.R. Barclay, L.T. Weaver, and D.J. Morrison Use of stable isotopes to measure the metabolic activity of the human intestinal microbiota Applied and Environment Microbiology 77 2011 8009 8014
33. M. Egert, A.A. de Graaf, A. Maathuis, P. de Waard, C.M. Plugge, and H. Smidt Identification of glucose-fermenting bacteria present in an in vitro model of the human intestine by RNA-stable isotope probing FEMS Microbiology Ecology 60 2007 126 135
34. P. Kovatcheva-Datchary, M. Egert, A. Maathuis, M. Rajilic-Stojanovic, A.A. de Graaf, and H. Smidt Linking phylogenetic identities of bacteria to starch fermentation in an in vitro model of the large intestine by RNA-based stable isotope probing Environmental Microbiology 11 2009 914 926
35. G. Dantas, M.O. Sommer, R.D. Oluwasegun, and G.M. Church Bacteria subsisting on antibiotics Science 320 2008 100 103
36. C.S. Riesenfeld, R.M. Goodman, and J. Handelsman Uncultured soil bacteria are a reservoir of new antibiotic resistance genes Environmental Microbiology 6 2004 981 989
37. H.K. Allen, L.A. Moe, J. Rodbumrer, A. Gaarder, and J. Handelsman Functional metagenomics reveals diverse beta-lactamases in a remote Alaskan soil The ISME Journal 3 2009 243 251
38. M.O. Sommer, G. Dantas, and G.M. Church Functional characterization of the antibiotic resistance reservoir in the human microflora Science 325 2009 1128 1131
39. T. Uchiyama, and K. Watanabe Substrate-induced gene expression (SIGEX) screening of metagenome libraries Nature Protocols 3 2008 1202 1212
40. T. Uchiyama, T. Abe, T. Ikemura, and K. Watanabe Substrate-induced gene-expression screening of environmental metagenome libraries for isolation of catabolic genes Nature Biotechnology 23 2005 88 93
41. L.S. Goodman, L.L. Brunton, B. Chabner, and B.C. Knollmann Goodman & Gilman's Pharmacological Basis of Therapeutics 12th ed. 2011 McGraw-Hill New York p. 2084
42. P.J. Turnbaugh, R.E. Ley, M. Hamady, C.M. Fraser-Liggett, R. Knight, and J.I. Gordon The human microbiome project Nature 449 2007 804 810
43. P. Goldman Biochemical pharmacology of the intestinal flora Annual Review of Pharmacology and Toxicology 18 1978 523 539
44. J. Hughes, and A. Crowe Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics Journal of Pharmacological Sciences 113 2010 315 324
45. E.J. Bach, and M. Reiter The difference in velocity between the lethal and inotropic action of dihydrodigoxin Naunyn-Schmiedebergs Archiv fur Experimentelle Pathologie und Pharmakologie 248 1964 437 449
46. U. Peters, L.C. Falk, and S.M. Kalman Digoxin metabolism in patients Archives of Internal Medicine 138 1978 1074 1076
47. J. Lindenbaum, D.G. Rund, V.P. Butler Jr., D. Tse-Eng, and J.R. Saha Inactivation of digoxin by the gut flora: reversal by antibiotic therapy New England Journal of Medicine 305 1981 789 794
48. J.F. Dobkin, J.R. Saha, V.P. Butler Jr., H.C. Neu, and J. Lindenbaum Digoxin-inactivating bacteria: identification in human gut flora Science 220 1983 325 327
49. H.S. Oz, and J.L. Ebersole Application of prodrugs to inflammatory diseases of the gut Molecules 13 2008 452 474
50. M.A. Peppercorn, and P. Goldman The role of intestinal bacteria in the metabolism of salicylazosulfapyridine Journal of Pharmacology and Experimental Therapeutics 181 1972 555 562
51. A.N. Wadworth, and Fitton A. Olsalazine A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease Drugs 41 1991 647 664
52. A. Vlaar, A. Hovestadt, T. van Laar, and B.R. Bloem The treatment of early Parkinson's disease: levodopa rehabilitated Practical Neurology 11 2011 145 152
53. J. Goole, and K. Amighi Levodopa delivery systems for the treatment of Parkinson's disease: an overview International Journal of Pharmaceutics 380 2009 1 15
54. B.R. Goldin, M.A. Peppercorn, and P. Goldman Contributions of host and intestinal microflora in the metabolism of l-DOPA by the rat Journal of Pharmacology and Experimental Therapeutics 186 1973 160 166
55. M. Lyte Microbial endocrinology as a basis for improved l-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori Medical Hypotheses 74 2010 895 897
56. M. Pierantozzi, A. Pietroiusti, L. Brusa, S. Galati, A. Stefani, and G. Lunardi Helicobacter pylori eradication and l-DOPA absorption in patients with pd and motor fluctuations Neurology 66 2006 1824 1829
57. M. Niehues, and A. Hensel In vitro interaction of l-DOPA with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability Journal of Pharmacy and Pharmacology 61 2009 1303 1307
58. M.S. Roberts, B.M. Magnusson, F.J. Burczynski, and M. Weiss Enterohepatic circulation: physiological, pharmacokinetic and clinical implications Clinical Pharmacokinetics 41 2002 751 790
59. H. Groh, K. Schade, and C. Horhold-Schubert Steroid metabolism with intestinal microorganisms Journal of Basic Microbiology 33 1993 59 72
60. C.I. Gill, and I.R. Rowland Diet and cancer: assessing the risk British Journal of Nutrition 88 Suppl. 1 2002 S73 S87
61. C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability American Journal of Clinical Nutrition 79 2004 727 747
62. A.J. McBain, and G.T. Macfarlane Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites Journal of Medical Microbiology 47 1998 407 416
63. H. Wiseman, K. Casey, E.A. Bowey, R. Duffy, M. Davies, and I.R. Rowland Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults American Journal of Clinical Nutrition 80 2004 692 699
64. B. Goldin, J. Dwyer, S.L. Gorbach, W. Gordon, and L. Swenson Influence of diet and age on fecal bacterial enzymes American Journal of Clinical Nutrition 31 1978 S136 S140
65. B.S. Reddy, J.H. Weisburger, and E.L. Wynder Fecal bacterial beta-glucuronidase: control by diet Science 183 1974 416 417
66. M. Dabek, S.I. McCrae, V.J. Stevens, S.H. Duncan, and P. Louis Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria FEMS Microbiology Ecology 66 2008 487 495
67. U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y.M. Rustum Irinotecan in the treatment of colorectal cancer: clinical overview Journal of Clinical Oncology 19 2001 1501 1518
68. A.M. Stringer, R.J. Gibson, R.M. Logan, J.M. Bowen, A.S. Yeoh, and D.M. Keefe Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats Cancer Biology and Therapy 7 2008 1919 1925
69. K. Takasuna, T. Hagiwara, M. Hirohashi, M. Kato, M. Nomura, and E. Nagai Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats Cancer Research 56 1996 3752 3757
70. D. Flieger, C. Klassert, S. Hainke, R. Keller, R. Kleinschmidt, and W. Fischbach Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma Oncology 72 2007 10 16
71. A. Stein, W. Voigt, and K. Jordan Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management Therapeutic Advances in Medical Oncology 2 2010 51 63
72. A. LoGuidice, B.D. Wallace, L. Bendel, M.R. Redinbo, and U.A. Boelsterli Pharmacologic targeting of bacterial beta-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice Journal of Pharmacology and Experimental Therapeutics 341 2012 447 454
73. M.V. Selma, J.C. Espin, and F.A. Tomas-Barberan Interaction between phenolics and gut microbiota: role in human health Journal of Agricultural and Food Chemistry 57 2009 6485 6501
74. M.R. Olthof, P.C. Hollman, P.L. Zock, and M.B. Katan Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans American Journal of Clinical Nutrition 73 2001 532 538
75. J.M. Laparra, and Y. Sanz Interactions of gut microbiota with functional food components and nutraceuticals Pharmacological Research 61 2010 219 225
76. D. Couteau, A.L. McCartney, G.R. Gibson, G. Williamson, and C.B. Faulds Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid Journal of Applied Microbiology 90 2001 873 881
77. W.R. Russell, L. Scobbie, A. Chesson, A.J. Richardson, C.S. Stewart, and S.H. Duncan Anti-inflammatory implications of the microbial transformation of dietary phenolic compounds Nutrition and Cancer 60 2008 636 642
78. M.H. van Nuenen, K. Venema, J.C. van der Woude, and E.J. Kuipers The metabolic activity of fecal microbiota from healthy individuals and patients with inflammatory bowel disease Digestive Diseases and Sciences 49 2004 485 491
79. I.R. Rowland, H. Wiseman, T.A. Sanders, H. Adlercreutz, and E.A. Bowey Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora Nutrition and Cancer 36 2000 27 32
80. C.E. Rufer, and S.E. Kulling Antioxidant activity of isoflavones and their major metabolites using different in vitro assays Journal of Agricultural and Food Chemistry 54 2006 2926 2931
81. H. Akaza, N. Miyanaga, N. Takashima, S. Naito, Y. Hirao, and T. Tsukamoto Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents Japanese Journal of Clinical Oncology 34 2004 86 89
82. F. Rafii, C. Davis, M. Park, T.M. Heinze, and R.D. Beger Variations in metabolism of the soy isoflavonoid daidzein by human intestinal microfloras from different individuals Archives of Microbiology 180 2003 11 16
83. Y. Shimada, M. Takahashi, N. Miyazawa, T. Ohtani, Y. Abiru, and S. Uchiyama Identification of two novel reductases involved in equol biosynthesis in Lactococcus strain 20-92 Journal of Molecular Microbiology and Biotechnology 21 2011 160 172
84. J.S. Jin, M. Kitahara, M. Sakamoto, M. Hattori, and Y. Benno Slackia equolifaciens sp. Nov., a human intestinal bacterium capable of producing equol International Journal of Systematic and Evolutionary Microbiology 60 2010 1721 1724
85. A. Matthies, G. Loh, M. Blaut, and A. Braune Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats Journal of Nutrition 142 2012 40 46
86. H. Tsuji, K. Moriyama, K. Nomoto, and H. Akaza Identification of an enzyme system for daidzein-to-equol conversion in Slackia sp. strain natts Applied and Environment Microbiology 78 2012 1228 1236
87. Y. Shimada, S. Yasuda, M. Takahashi, T. Hayashi, N. Miyazawa, and I. Sato Cloning and expression of a novel NADP(H)-dependent daidzein reductase, an enzyme involved in the metabolism of daidzein, from equol-producing Lactococcus strain 20-92 Applied and Environment Microbiology 76 2010 5892 5901
88. M. al-Waiz, M. Mikov, S.C. Mitchell, and R.L. Smith The exogenous origin of trimethylamine in the mouse Metabolism: Clinical and Experimental 41 1992 135 136
89. B. Bjorkholm, C.M. Bok, A. Lundin, J. Rafter, M.L. Hibberd, and S. Pettersson Intestinal microbiota regulate xenobiotic metabolism in the liver PLoS ONE 4 2009 e6958
90. N. Gamage, A. Barnett, N. Hempel, R.G. Duggleby, K.F. Windmill, and J.L. Martin Human sulfotransferases and their role in chemical metabolism Toxicological Sciences 90 2006 5 22
91. J. Qin, R. Li, J. Raes, M. Arumugam, K.S. Burgdorf, and C. Manichanh A human gut microbial gene catalogue established by metagenomic sequencing Nature 464 2010 59 65
92. K.E. Nelson, G.M. Weinstock, S.K. Highlander, K.C. Worley, H.H. Creasy, and J.R. Wortman A catalog of reference genomes from the human microbiome Science 328 2010 994 999
93. T. Yatsunenko, F.E. Rey, M.J. Manary, I. Trehan, M.G. Dominguez-Bello, and M. Contreras Human gut microbiome viewed across age and geography Nature 486 2012 222 227
94. T.H.M.P. Consortium Structure, function and diversity of the healthy human microbiome Nature 486 2012 207 214
95. G. Van den Mooter, B. Maris, C. Samyn, P. Augustijns, and R. Kinget Use of azo polymers for colon-specific drug delivery Journal of Pharmaceutical Sciences 86 1997 1321 1327
96. M.S. Chavan, V.P. Sant, and M.S. Nagarsenker Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in vitro evaluation Journal of Pharmacy and Pharmacology 53 2001 895 900
97. C.S. Smillie, M.B. Smith, J. Friedman, O.X. Cordero, L.A. David, and E.J. Alm Ecology drives a global network of gene exchange connecting the human microbiome Nature 480 2011 241 244
98. J.H. Hehemann, G. Correc, T. Barbeyron, W. Helbert, M. Czjzek, and G. Michel Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota Nature 464 2010 908 912
99. J.R. Cole, Q. Wang, E. Cardenas, J. Fish, B. Chai, and R.J. Farris The ribosomal database project: improved alignments and new tools for rRNA analysis Nucleic Acids Research 37 2009 D141 D145
100. I. Letunic, and P. Bork Interactive tree of life v2: online annotation and display of phylogenetic trees made easy Nucleic Acids Research 39 2011 W475 W478
101. G.W. Elmer, and R.P. Remmel Role of the intestinal microflora in clonazepam metabolism in the rat Xenobiotica 14 1984 829 840
102. H.A. Strong, A.G. Renwick, C.F. George, Y.F. Liu, and M.J. Hill The reduction of sulphinpyrazone and sulindac by intestinal bacteria Xenobiotica 17 1987 685 696
103. R. Gingell, J.W. Bridges, and R.T. Williams The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat Xenobiotica 1 1971 143 156
104. R.P. Chan, D.J. Pope, A.P. Gilbert, P.J. Sacra, J.H. Baron, and J.E. Lennard-Jones Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide Digestive Diseases and Sciences 28 1983 609 615
105. S. Takeno, and T. Sakai Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction Teratology 44 1991 209 214
106. K. Watanabe, S. Yamashita, K. Furuno, H. Kawasaki, and Y. Gomita Metabolism of omeprazole by gut flora in rats Journal of Pharmaceutical Sciences 84 1995 516 517
107. R.L. Koch, and P. Goldman The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid Journal of Pharmacology and Experimental Therapeutics 208 1979 406 410
108. R.L. Koch, B.B. Beaulieu Jr., and P. Goldman Role of the intestinal flora in the metabolism of misonidazole Biochemical Pharmacology 29 1980 3281 3284
109. S. Kitamura, K. Sugihara, M. Kuwasako, and K. Tatsumi The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide Journal of Pharmacy and Pharmacology 49 1997 253 256
110. M.S. Abu Shamat, and A.H. Beckett Glyceryl trinitrite: metabolism by the intestinal flora The Journal of Pharmacy and Pharmacology 35 1983
111. P. Iveson, W.E. Lindup, D.V. Parke, and R.T. Williams The metabolism of carbenoxolone in the rat Xenobiotica 1 1971 79 95
112. D.M. Valerino Studies of the metabolism of methotrexate Ii. Isolation and identification of several unconjugated aminopteridines as metabolites in the rat Research Communications in Chemical Pathology and Pharmacology 4 1972 529 542
113. C.T. Walsh, and R.R. Levine Studies of the enterohepatic circulation of morphine in the rat Journal of Pharmacology and Experimental Therapeutics 195 1975 303 310
114. K. Kobashi, T. Nishimura, M. Kusaka, M. Hattori, and T. Namba Metabolism of sennosides by human intestinal bacteria Planta Medica 40 1980 225 236
115. H. Okuda, K. Ogura, A. Kato, H. Takubo, and T. Watabe A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs Journal of Pharmacology and Experimental Therapeutics 287 1998 791 799
116. S.G. Elkington, M.H. Floch, and H.O. Conn Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial New England Journal of Medicine 281 1969 408 412
117. B.E. Harris, B.W. Manning, T.W. Federle, and R.B. Diasio Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora Antimicrobial Agents and Chemotherapy 29 1986 44 48
118. J. Caldwell, and G.M. Hawksworth The demethylation of methamphetamine by intestinal microflora Journal of Pharmacy and Pharmacology 25 1973 422 424
119. G.E. Smith, and L.A. Griffiths Metabolism of N-acylated and O-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro Xenobiotica 4 1974 477 487
120. A.W. Basit, and L.F. Lacey Colonic metabolism of ranitidine: implications for its delivery and absorption International Journal of Pharmaceutics 227 2001 157 165
121. A.W. Basit, J.M. Newton, and L.F. Lacey Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora International Journal of Pharmaceutics 237 2002 23 33
122. H. Tozaki, Y. Emi, E. Horisaka, T. Fujita, A. Yamamoto, and S. Muranishi Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon Journal of Pharmacy and Pharmacology 49 1997 164 168
123. M. Abu Shamat The role of gastrointestinal microflora in the metabolism of drugs International Journal of Pharmaceutics 97 1993 13
124. R.V. Smith Metabolism of drugs and other foreign compounds by intestinal microorganisms World Review of Nutrition and Dietetics 29 1978 60 76
125. P.J. Tobin, H.M. Dodds, S. Clarke, M. Schnitzler, and L.P. Rivory The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours Oncology Reports 10 2003 1977 1979
126. R. Holt The bacterial degradation of chloramphenicol Lancet 1 1967 1259 1260
127. Y.Z. Shu, D.G. Kingston, R.L. Van Tassell, and T.D. Wilkins Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria Xenobiotica 21 1991 737 750
128. B.J. Dull, K. Salata, and P. Goldman Role of the intestinal flora in the acetylation of sulfasalazine metabolites Biochemical Pharmacology 36 1987 3772 3774
129. W. Meuldermans, J. Hendrickx, G. Mannens, K. Lavrijsen, C. Janssen, and J. Bracke The metabolism and excretion of risperidone after oral administration in rats and dogs Drug Metabolism and Disposition: The Biological Fate of Chemicals 22 1994 129 138
130. I. Sasaki, T. Tamura, T. Shibakawa, T. Fujita, M. Murakami, and A. Yamamoto Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms Pharmaceutical Research 14 1997 1004 1007
131. K. Yoshisue, H. Masuda, E. Matsushima, K. Ikeda, S. Nagayama, and Y. Kawaguchi Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats Drug Metabolism and Disposition: The Biological Fate of Chemicals 28 2000 1162 1167
132. N.K. Lee, S.H. Choi, S.H. Park, E.K. Park, and D.H. Kim Antiallergic activity of hesperidin is activated by intestinal microflora Pharmacology 71 2004 174 180
133. H. Nakayama, T. Kinouchi, K. Kataoka, S. Akimoto, Y. Matsuda, and Y. Ohnishi Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil Pharmacogenetics 7 1997 35 43